Biocrucible Ltd
Registered name: BIOCRUCIBLE LTD
Biocrucible Ltd made £923k revenue and a £8.6m loss in the year to 31 Dec 2024.
Biocrucible Ltd’s revenue grew 364% to £923k in the year to 31 Dec 2024, with a loss of £8.6m and 87 employees. The company is classified under “research and experimental development on biotechnology” and is based in Saffron Walden; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- Saffron Walden, East of England
- Age
- 8 yrs · since 2018
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “KKR Sapphiros L.P.”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|
| Disclosure | Full P&L | Full P&L |
| Profit & loss | ||
| Revenue (turnover) | £199k | £923k |
| Gross profit | £199k | £923k |
| Operating profit | −£4.9m | −£8.3m |
| Profit before tax | −£4.9m | −£8.3m |
| Profit after tax | −£5.1m | −£8.6m |
| Profit (best available) | −£5.1m | −£8.6m |
| Staff costs | £4.7m | £5.9m |
| Employees (average) | 74 | 87 |
| Ratios | ||
| Profit margin | −2554% | −932.7% |
| Gross margin | 100% | 100% |
| Revenue per employee | £2.7k | £10.6k |
| Profit per employee | −£68.7k | −£99k |
| Growth (year on year) | ||
| Revenue growth | — | ▲363.8% |
| Headcount growth | — | ▲17.6% |
| Balance sheet — indirect signals, not revenue | ||
| Cash at bank | £1.1m | £91.9k |
| Net assets | −£16.1m | −£24.7m |
| Fixed assets | £2.1m | £2m |
| Current assets | £5.7m | £4.8m |
| Debtors | £175k | £11.6k |
| Deferred income | £3.6m | £1.7m |
| Cash from operations | £2m | −£209k |
| Source | FullAccounts · bulk data Dec 2025 | FullAccounts · bulk data Dec 2025 |
How the business works
- Profit margin
- −932.7%
- Profit ÷ revenue.
- Gross margin
- 100%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £10.6k
- Revenue ÷ average employees.
- Profit per employee
- −£99k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 218.8%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 186.5%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 1.3%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£24.7m
- Cash at bank
- ▼92%
- Now £91.9k
- Headcount
- ▲18%
- Now 87
- Deferred income
- ▼53%
- Now £1.7m
- Fixed assets
- ▼3%
- Now £2m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Collaborative Community Against Coronavirus CICLondon · Research and experimental development on biotechnology
- Revenue
- £786k
- Profit
- £29.9k
- Staff
- 0
- Nuritas UK LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £88.8k
- Staff
- 4
- Adorx Therapeutics LimitedEdinburgh · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £211k
- Staff
- 0
- Clinicology Ltd.Guildford · Research and experimental development on biotechnology
- Revenue
- £1.4m
- Profit
- £79.1k
- Staff
- 7
Sources
Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£8.6m), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.